Patents Assigned to PEKING UNIVERSITY FIRST HOSPITAL
  • Publication number: 20250027936
    Abstract: The present disclosure provides an immunoassay device, and a preparation method and use thereof, and belongs to the technical field of biological detection. In the present disclosure, the immunoassay device includes a test strip and a thin film pump, where a driving component in the thin film pump is connected to a printed circuit board (PCB) or a chip outside the thin film pump through a wire, to control starting or turning off of the thin film pump; and a liquid outlet of the thin film pump is closely attached to a top of a conjugate pad of the test strip, or a top of a sample pad of the test strip, or a top of a middle part between the conjugate pad and the sample pad.
    Type: Application
    Filed: January 9, 2024
    Publication date: January 23, 2025
    Applicants: Peking University, PEKING UNIVERSITY FIRST HOSPITAL
    Inventors: Yue CUI, Li YANG
  • Publication number: 20240084392
    Abstract: The present invention relates to the field of tumor grade detection. Specifically disclosed are a gene combination for human tumor grading, and a use thereof. The gene combination for human tumor grading consists of a gene set A and a gene fragment set B. The gene combination for human tumor grading is obtained from high-throughput sequencing data of an actual renal cancer case of the Peking University First Hospital by means of specific pairing and clustering, is derived from real data, and can be used for malignancy degree grading and prognosis prediction for renal cancer and pan-cancer.
    Type: Application
    Filed: March 2, 2022
    Publication date: March 14, 2024
    Applicant: PEKING UNIVERSITY FIRST HOSPITAL
    Inventors: Gengyan XIONG, Shiming HE, Zhisong HE, Liqun ZHOU
  • Publication number: 20230097420
    Abstract: An indazole hydrazide compound, as represented in formula (I); wherein, R is selected from substituted alkyl, substituted alkenyl and substituted phenyl; substituent in the substituted alkyl and substituted alkenyl includes phenyl and/or substituted phenyl; R? is selected from H and alkyl. Compared with the prior art, the above indole hydrazide compound can be used as integrin av?3 receptor antagonist. Besides, it has obvious anti-prostate cancer activity and has a significant inhibitory effect on enzalutamide-resistant cell lines. In addition, the above-mentioned compound has obvious anti-tumor angiogenesis activity and can be used in the preparation of anti-tumor angiogenesis drugs to inhibit tumor angiogenesis.
    Type: Application
    Filed: November 26, 2021
    Publication date: March 30, 2023
    Applicant: PEKING UNIVERSITY FIRST HOSPITAL
    Inventors: Yimin CUI, Xiaocong PANG, Xu HE, Yanlun GU, Zhenming LIU, Song SONG, Xia ZHAO, Ying ZHOU, Qian XIANG, Junling ZHANG, Ran XIE, Xiaojiao SUN, Zhuo ZHANG
  • Patent number: 11293916
    Abstract: A method comprises adding reagent I to a sample to be detected, incubating to obtain a first detection sample, and detecting to obtain a first absorbance value A1 of the sample to be detected; adding reagent II to the first detection sample, incubating to obtain a second detection sample, and detecting to obtain a second absorbance value A2 of the sample to be detected; adding reagent I to a standard sample, incubating to obtain a first detection standard, and detecting to obtain a first absorbance value B1 of the standard; adding reagent II to the first detection standard, incubating to obtain a second detection standard, and detecting to obtain a second absorbance value B2 of the standard; and using A1 and A2, and B1 and B2 to obtain a concentration level of complement factor H in the sample to be detected.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 5, 2022
    Assignees: PEKING UNIVERSITY FIRST HOSPITAL
    Inventors: Zhongling Liu, Minghui Zhao, Feng Yu